comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 23:04:28 - browse：8

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： David Ricks of Eli Lilly: best biopharma CEO of 2023

Wikipedia

WSS

FDA endorses new sterilization method for medical devices

Mass General, Mayo Clinic look to monetize custom

Immunocompromised patients offer clues on chronic Covid

Dana Farber says 6 studies to be retracted and 31 corrected

CVS is on a mission to consolidate health care. Will it work?

Flu vaccine reformulation won't be easy, manufacturers warn

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Flu vaccine reformulation won't be easy, manufacturers warn

Apple is now the first public company to be valued at $3 trillion

Inaction leaves children at risk from dangerous chemotherapy drug

Trump demands the U.S. pay no more for drugs than other countries … again

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Violet CEO on training clinicians to promote more inclusive care

Dobbs anniversary: the lost opportunity of abortion as health care

Three trends to watch in biotech in 2024

focus

There's an unseen cost to disruptive road

Printout prescription drug information shouldn’t go digital

Update the Apgar Score to remove skin color

Can sheer will power keep patients alive in their dying hours?

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Dog Aging Project founders on what lies ahead after losing funding

Wikipedia

hotspot

focus

explore